China (Mainland)
Premiumsupplier 
Reversine, CAS NO.656820-32-5
- FOB Price: USD: 1.00-1.00 /Gram Get Latest Price
- Min.Order: 100 Gram
- Payment Terms: L/C
- Available Specifications:
≥98.0%(100-500)Gram≥98.0%(1000-5000)Gram
- Product Details
Keywords
- Reversine,
- Reversine,
- 656820-32-5
Quick Details
- ProName: Reversine,
- CasNo: 656820-32-5
- Molecular Formula: C21H27N7O
- Appearance: close to white solid
- Application: CAS：656820-32-5； Small molecule inhib...
- DeliveryTime: 2 months
- PackAge: 100g,500g,1kg,25kg
- Port: shang hai
- ProductionCapacity: 1000 Gram/Month
- Purity: 98%
- Storage: refrigerate
- Transportation: shipping
- LimitNum: 100 Gram
Superiority
We are committed to provide excellence in researching, manufacturing and drug discovery process.
Our research team of scientists consists of western-trained Ph.D.s with experience and capabilities in drug R&D methodologies and medicinal chemistry.
Details
Reversine, a small synthetic purine analogue (2,6-disubstituted purine), is a potent inhibitior of Aurora A/B/C with IC50s of 150-500 nM.
IC50 Value: 150 nM (Aurora Kinase A); 500 nM (Aurora Kinase B); 400 nM (Aurora Kinase C) [1]
Target: pan-Aurora Kinase
in vitro: Reversine induced apoptosis in PDTC cells with caspase-3 and caspase-8 activation, but not caspase-9. Use of a pan-caspase inhibitor before treatment with reversine attenuated cell death [2]. Reversine significantly suppressed the proliferation of two OSCC cell lines (OC2 and OCSL) and markedly rendered cell cycle arrest at G2/M stage. Reversine also induced cell death via both caspase-dependent and -independent apoptosis. In addition,reversine could inhibit Akt/mTORC1 signaling pathway, accounting for its ability to induce autophagy [3]. Reversine pre-treatment, at very low concentration (50 nM), caused a marked increase in the differentiation yields of both BMSCs and ASCs [4].
in vivo: In the therapeutic mouse model, tumor weight and tumor volume of cervical cancer bearing mice was more reduced when compared with the control agents (P < 0.05) in tumor-bearing mice [5].